Department of Traditional Chinese Medicine, the First Affiliated Hospital of Jinan University, Guangzhou 510630, China.
Department of Cardiology, Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou 510000, China.
J Tradit Chin Med. 2023 Oct;43(6):1227-1233. doi: 10.19852/j.cnki.jtcm.20231008.001.
OBJECTIVE: To assess the effectivess of Shenshu Guanxin recipe granules (, SGR) in improving exercise tolerance and the quality of life in patients with Stable Angina Pectoris (SAP). METHODS: A total of 189 patients were consecutively enrolled between December 2012 and December 2014. The included patients were randomly assigned to SGR and placebo groups. The primary endpoints included mainly the results of treadmill exercise test and Seattle Angina Questionnaire (SAQ) during 12 weeks of treatment. RESULTS: After 12 weeks of treatment, SGR extended the time of exercise-induced ST-segment depression of 0.1 MV, lowered the maximum ST-segment depression, and shortened the duration of ST-segment depression in patients with SAP in southern China. Besides, the study also proved that SGR could improve the quality of life and functional status of patients with SAP. CONCLUSIONS: SGR showed a positive effect on exercise tolerance compared with the placebo besides optimal medical therapy. Also, the study proved that SGR could improve the SAQ score of the patients.
目的：评价参芍冠心方颗粒对稳定型心绞痛患者运动耐量和生活质量的影响。
方法：2012 年 12 月至 2014 年 12 月连续纳入 189 例患者，按随机数字表法分为参芍冠心方颗粒组和安慰剂组。主要终点为治疗 12 周时的平板运动试验和西雅图心绞痛问卷（SAQ）结果。
结果：治疗 12 周后，参芍冠心方颗粒组可延长运动诱导的 ST 段压低 0.1 mV，降低最大 ST 段压低，缩短 ST 段压低持续时间，改善中国南方地区稳定型心绞痛患者的运动耐量。此外，该研究还证明参芍冠心方颗粒可改善稳定型心绞痛患者的生活质量和功能状态。
结论：与最佳药物治疗相比，参芍冠心方颗粒对运动耐量具有积极影响。此外，该研究证明参芍冠心方颗粒可提高患者的 SAQ 评分。
J Am Heart Assoc. 2017-9-8
Biomed Pharmacother. 2018-11-5
Zotero 插件